Clinical Trials Logo

Clinical Trial Summary

Small fiber neuropathy (SFN) is a condition that is dominated by invalidating neuropathic pain. Pharmacological neuropathic pain treatment is often disappointing, since pain reduction is mostly slight and side effects can be debilitating. Although neuropathic pain is caused by a lesion of the somatosensory system, also psychological factors, such as fear and catastrophizing, appear to play a role in the origin and maintenance of disability in chronic pain. Rehabilitation based on pain education and cognitive behavioral treatment including elements of acceptance and commitment therapy, exposure in vivo or graded activity can be performed to influence these factors. To date no specific rehabilitation programs are available for patients diagnosed with SFN.


Clinical Trial Description

Small fiber neuropathy (SFN) presents with neuropathic pain and autonomic dysfunction, caused by damage of the myelinated Aδ- and unmyelinated C-fibers. Neuropathic pain in SFN is chronic and severe. In 47% of the SFN cases, an underlying cause can be found. The diagnosis of SFN is established on the clinical signs and symptoms, in combination with reduced intra-epidermal nerve fiber density in the skin biopsy and/or abnormal quantitative sensory testing, with no abnormalities in the nerve conduction test (no large fiber involvement). Without underlying cause or when causative treatment is not sufficient, the treatment is focused on symptomatic neuropathic pain relief. Nevertheless, current pharmacological treatment is not sufficient enough in pain relief. In less than 50% of the pain patients, pain reduction of 30-40% has been observed with the most potent analgesia. Besides the lack of effectiveness of pharmacological medication, side effects and abuse are reported. These insufficient treatment options of SFN enables the necessity to search for other possible treatments. In the treatment of (chronic) pain disability, a biopsychosocial approach seems to be effective in reducing disability and quality of life (QOL) in SFN. As we know based on earlier studies, chronic (neuropathic) pain, such as SFN, is influenced by several psychological factors, especially in causing and perpetuating pain. First, catastrophizing is one of those disabling psychological factors, which is defined as exaggerated negative mental set brought to bear during actual or anticipated pain experience Catastrophizing is seen as a precursor of pain, rather than consequence. Evidence showed a relation between the severity of chronic neuropathic pain and catastrophizing. Pain catastrophizing has been correlated to pain intensity, independent of physical impairment. In chronic pain, negative and catastrophic thoughts about illness often increase the level of disability. It seems that catastrophizing is one of the factors influencing QOL. Second, fear is another disabling psychological factor. Fear of pain can result in avoidance behavior and reduction of daily activities. Avoidance is the behavior aimed at postponing or preventing an aversive situation from occurring, which are mostly seen as a threat. According to the basic fear avoidance (conditioning) model, chronic pain and disability are induced by behavior. Neutral stimulus receives a negative load. In daily activities, these stimuli will remind patients to the painful experiences and so predicting pain. The intensity of pain combined with psychosocial factors can result in escape and avoidance behavior with eventually an impact for the level of physical activity. These factors can be treated with cognitive behavioral therapy (CBT), which aims to change the behavior, mindset, or feelings of the patient, helping to experience less distress, enjoying more and being more productive. Varying CBT modalities exists: exposure in vivo, acceptance and commitment therapy (ACT), and graded activity (GA), which will be discussed. All the mentioned modalities will be provided by a treatment team consisting of a psychologist and an occupational therapist, whom both are experienced in the modalities of CBT. For every patient an individualized program will be designed based on the results of a screening. First, a patient will receive education about disabling factors that interfere with functioning in their personal situation. Thereafter, an individual treatment plan containing elements that specifically target disabling factors in the patient's situation will guide further treatment. Additional treatment elements can be based on three cognitive behavioral approaches: exposure in vivo, graded activity and acceptance commitment therapy (ACT). One or more modalities can be combined. The main (primary) objective is to test the effectiveness of a personally tailored rehabilitation treatment targeting the specific psychological and behavioral factors related to decreasing disability, and improving QOL in SFN. The secondary objective is the personally tailored rehabilitation treatment program will have decrease of pain intensity, mood, and pain catastrophizing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05798949
Study type Interventional
Source Academisch Ziekenhuis Maastricht
Contact A. Damci, MD
Phone 0031433876584
Email aysun.damci@mumc.nl
Status Recruiting
Phase N/A
Start date March 9, 2023
Completion date October 2025

See also
  Status Clinical Trial Phase
Completed NCT02537951 - Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study N/A
Completed NCT01911975 - Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy Phase 3
Completed NCT03304522 - A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy Phase 2
Recruiting NCT04310644 - Autonomic Small Fiber Neuropathy and Ehlers Danlos Syndromes - Prospective Study and Registry
Completed NCT03912220 - Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration Phase 2
Completed NCT03401073 - IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3 Phase 2
Recruiting NCT03889080 - fMRI-study in Patients With Small Fiber Neuropathy
Completed NCT03447756 - Titration Study of ABX-1431 Phase 1
Recruiting NCT04835779 - Biometric and Biological Data for Diagnosis and Therapy of Pain Patients
Suspended NCT04611048 - Establishing Normative Values for Thermal Detection and Pain Threshold Established by the Psi Method N/A
Not yet recruiting NCT04170205 - Causes Associated With Small Fiber Neuropathy (SFN).
Recruiting NCT05389566 - Diabetes, Falls, and Fractures
Terminated NCT03339336 - Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy Phase 2
Enrolling by invitation NCT05921097 - Comparison of Histamine and Local Heating for Evoking the Axon-reflex Flare Response in Diabetes
Completed NCT02637700 - Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy Phase 2
Recruiting NCT04759443 - Detection of Small Fiber Neuropathy Using Skin Properties
Terminated NCT02905396 - Spinal Cord Stimulation in Small Fibre Neuropathy N/A
Completed NCT05380804 - Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome
Recruiting NCT03509064 - Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
Completed NCT05993871 - Diabetic Small Fiber Neuropathy: Clinical, Electrophysiological and Neurosonographic Study